Even with apparent indicators of efficacy, clinicians still have questions about using Biogen, Inc. and Eisai Co., Ltd.’s Leqembi (lecanimab-irmb) in Alzheimer’s disease patients. Many likely require more study and some could be limiting uptake.
Lingering Leqembi Question: When Should Treatment Stop?
Several questions about the anti-amyloid product used to treat Alzheimer’s remain, which could affirm calls for more US FDA, CMS and NIH collaboration on research.
